Corcept Therapeutics Q3 2026 Earnings Conference Call - CORCEPT THERAPEUTICS INC

Financial Performance:

• Third-quarter 2026 revenue reached $340.5 million, representing a 33% sequential increase and a 64% year-over-year growth.
• Revenue breakdown: Quorum and authorized generics contributed $249.1 million; LaFerriere (Mifepristone) generated $91.4 million.
• Net income for the quarter was $126.8 million, a significant rise from $43 million in Q2 and $19.7 million in the prior-year period.
• Cash and investments totaled $662 million as of September 30, reflecting an $118 million increase during the quarter.
• The company repurchased $44 million of common stock in Q3 and saw proceeds from stock option exercises and RSU vesting.

Guidance and Future Outlook:

• Corecept reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion despite strong Q3 performance.
• Management projects the existing Cushing syndrome business could generate at least $2 billion in annual revenue by the end of the decade.
• If Reliquarolant receives approval, revenue from the Cushing syndrome segment is projected to grow between $3 billion and $5 billion by 2030.
• Lithiole is expected to generate over $1 billion in annual revenue in the future.
• FDA decision deadline for Reliquarolant (Cushing syndrome NDA) is set for December 17.
• Key clinical trial data from BELLA, TRIDENT, and Synergy studies are expected to be released by the end of 2027.

Business Segments and Product Lines:

• Endocrinology: LaFerriere (Mifepristone) continues to drive growth as medical societies (ADA, ACE) increasingly recommend screening for hypercortisolism in difficult-to-control diabetes patients.
• Oncology: Lithiole (Relacorilant) revenue grew 29% to $91.4 million in Q3, with over 2,300 patients treated by more than 1,700 physicians since its April 1 launch.
• Pipeline (Oncology): The BELLA trial (Arm A) showed Lithiole combined with nab-paclitaxel and bevacizumab yielded a median progression-free survival of 7.2 months and a 59% objective response rate.
• Pipeline (Metabolic): Miracoralin demonstrated dose-dependent reductions in liver fat and 19.2% fibrosis improvement in the Phase IIb Monarch study for MASH.
• Pipeline (Neurological): A Phase III ALS trial is planned to begin next year following promising Phase II DASL data showing reduced early mortality.

Market and Competitive Landscape:

• Lithiole is positioned to become the market leader in platinum-resistant ovarian cancer due to its unique mechanism of action (GR antagonism) and lack of required biomarker screening.
• The hypercortisolism market is being expanded by new data suggesting it is more prevalent than previously understood, with 24% of difficult-to-treat diabetes patients identified as hypercortisolism-positive.
• Management notes that competitors (e.g., ADCs or other chemo-agents) do not cure platinum-resistant ovarian cancer, necessitating continued treatment with differentiated mechanisms like Lithiole.
• The strategy emphasizes combining Lithiole with standard-of-care agents (chemotherapy, immunotherapy, ADCs) to treat earlier lines of disease and other solid tumors.

Risks and Challenges:

• Reliquarolant's approval depends on the FDA's review of the resubmitted NDA, with a specific focus on the statistical analysis of global endpoints (glucose, weight, hypertension).
• Potential market risks include the pace of guideline incorporation (ADA/ACE recommendations) and physician adoption of new screening protocols.
• MASH pipeline involves transitioning from a twice-weekly to a daily (with intermittent dosing) regimen to optimize efficacy while managing safety signals (ALT rises).
• General risks associated with clinical trial timelines and the uncertainty of future data readouts for indications including pancreatic cancer, endometrial cancer, and ALS.

Management Commentary and Tone:

• Management expressed high confidence in the "GR antagonism" platform, describing it as a disease-modifying mechanism with broad applicability across solid tumors.
• New President of Endocrinology, Justin Gunn, emphasized the "untapped potential" of the hypercortisolism diagnosis and the momentum from landmark clinical studies.
• CEO Joe Bell highlighted the platform's versatility, noting its potential to treat any solid tumor expressing the glucocorticoid receptor in combination with various anti-cancer agents.
• The tone was optimistic yet pragmatic regarding the static revenue guidance, attributing it to probabilistic modeling and the maturity of current product launches.

Analyst Questions and Answers:

• Lithiole Dynamics: Analysts asked about the relationship between new patient starts, treatment duration, and revenue. Management confirmed growth in repeat prescribing and earlier-line usage, particularly in patients without prior bevacizumab exposure.
• Guidance Rationale: When asked why guidance was not raised despite strong growth, CFO Adibak Makkari cited the company's standard probabilistic approach and the fact that the midpoint of the range represents their best thinking.
• Competitive Landscape: Regarding GenMab's RENA-S data, management maintained that Lithiole's differentiated immune-modulating mechanism and combination potential secure its future role in the market.
• Cushing Syndrome Launch Strategy: For Reliquarolant, management clarified the focus will be on identifying new, treatment-naive patients rather than switching existing Korlym patients, though switching profiles exist.
• MASH Dosing: Management explained the shift to a 100 mg daily dose for Miracoralin based on dose-dependent responses observed in the Monarch study and Phase I data, aiming to maximize liver fat reduction while monitoring safety.

Other Key Points:

• Organizational Change: Justin Gunn assumed the role of President of the Endocrinology Division in October, having previously led sales for the Oncology division.
• Regulatory Milestones: The company successfully performed the requested global statistical test for the Reliquarolant NDA, leading to the FDA's acceptance of the resubmission.
• Clinical Expansion: New trials are underway to evaluate Lithiole in endometrial cancer (RMC arm of BELLA), platinum-sensitive ovarian cancer (BELLA Arm B), and pancreatic cancer (TRIDENT trial).
• Data Readouts: Multiple studies (Synergy Phase 1b for immunotherapy combinations, TRIDENT for pancreatic cancer) are targeted for completion and results by the end of 2027.